Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · December 13, 2021

Adalimumab vs Vedolizumab for Treatment of Ulcerative Colitis and Crohn's Disease

Inflammatory Bowel Diseases


Additional Info

Disclosure statements are available on the authors' profiles:

Inflammatory Bowel Diseases
Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD
Inflamm. Bowel Dis. 2021 Nov 09;[EPub Ahead of Print], A Moens, B Verstockt, D Alsoud, J Sabino, M Ferrante, S Vermeire

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading